![Manfred Reichl](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Manfred Reichl
Chairman at APEIRON Biologics AG
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Peter Llewellyn-Davies | M | 66 |
APEIRON Biologics AG
![]() APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 7 years |
Helmut Schühsler | M | 65 |
APEIRON Biologics AG
![]() APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | - |
Ulrich Granzer | M | 63 |
APEIRON Biologics AG
![]() APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 3 years |
Rudolf Schwarzinger | M | - |
HELIOVIS AG
![]() HELIOVIS AG Electric UtilitiesUtilities HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria. | - |
Wolfram Krendlesberger | M | - |
HELIOVIS AG
![]() HELIOVIS AG Electric UtilitiesUtilities HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria. | - |
Holger Sindemann | M | - |
HELIOVIS AG
![]() HELIOVIS AG Electric UtilitiesUtilities HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria. | - |
Günter Ehweiner | M | 45 |
HELIOVIS AG
![]() HELIOVIS AG Electric UtilitiesUtilities HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria. | - |
Ronald Gerns | M | - |
HELIOVIS AG
![]() HELIOVIS AG Electric UtilitiesUtilities HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria. | - |
Boris Dorin | M | - |
HELIOVIS AG
![]() HELIOVIS AG Electric UtilitiesUtilities HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria. | - |
Erwin Rasinger | M | - |
APEIRON Biologics AG
![]() APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | - |
Edward Charles | M | - |
APEIRON Biologics AG
![]() APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 4 years |
Andreas Gerber | M | - |
APEIRON Biologics AG
![]() APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Josef Penninger | M | - |
APEIRON Biologics AG
![]() APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 16 years |
Rainer C. Burian | M | - |
APEIRON Biologics AG
![]() APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | - |
Statistics
Country | Connections | % of total |
---|---|---|
Austria | 14 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Manfred Reichl
- Personal Network